NR1I2 Antibody - N-terminal region (ARP36016_P050)

• Product Number: ARP36016_P050
• Name: NR1I2 Antibody - N-terminal region (ARP36016_P050)
• Protein Size (# AA): 434 amino acids
• Molecular Weight: 50 kDa
• NCBI Gene Id: 8856
• Host: Rabbit
• Clonality: Polyclonal
• Concentration: 0.5 mg/ml
• Gene Full Name: Nuclear receptor subfamily 1, group I, member 2
• Alias Symbols: BXR, PAR, PRR, PXR, SAR, SXR, ONR1, PAR1, PAR2, PARq
• Peptide Sequence: Synthetic peptide located within the following region: KKEMIMSDEAVEERRALIKRKKSERTGTQPLGVQGLTEEQRMMIRELMDA
• Product Format: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
• Reference: Hesselink,D.A., (2008) Pharmacogenomics 9 (6), 783-789
• Description of Target: NR1I2 belongs to the nuclear receptor superfamily, members of which are transcription factors characterized by a ligand-binding domain and a DNA-binding domain. NR1I2 contains a zinc finger domain.NR1I2 is a transcriptional regulator of the cytochrome P450 gene CYP3A4, binding to the response element of the CYP3A4 promoter as a heterodimer with the 9-cis retinoic acid receptor RXR. It is activated by a range of compounds that induce CYP3A4, including dexamethasone and rifampicin. NR1I2 belongs to the nuclear receptor superfamily, members of which are transcription factors characterized by a ligand-binding domain and a DNA-binding domain. This gene product belongs to the nuclear receptor superfamily, members of which are transcription factors characterized by a ligand-binding domain and a DNA-binding domain. The encoded protein is a transcriptional regulator of the cytochrome P450 gene CYP3A4, binding to the response element of the CYP3A4 promoter as a heterodimer with the 9-cis retinoic acid receptor RXR. It is activated by a range of compounds that induce CYP3A4, including dexamethasone and rifampicin. Several alternatively spliced transcripts encoding different isoforms, some of which use non-AUG (CUG) translation initiation codon, have been described for this gene. Additional transcript variants exist, however, they have not been fully characterized.
• Protein Interactions: NCOA1; RPS6KB1; UBC; RBBP7; DDB1; UBR5; DYRK2; NCOR2; SDF4; NCOA3; TFAP2C; MAPK7; NFATC4; HSP90AA1; FGR; ATP6AP1; RXRA; RBCK1; NCOA2; SUMO1; SUMO2; SUMO3; NCOA6; SRC; RXRG; RXRB; CHMP1A; NUCB2; ACTN2; PPARGC1A; EIF3I; TADA3; NCOR1; PRMT1; NR1I2; PSMC5; PO
• Reconstitution and Storage: For short term use, store at 2-8C up to 1 week. For long term storage, store at -20C in small aliquots to prevent freeze-thaw cycles.
• Enhanced Validation: Relative Expression (Western Blot)
  
• Blocking Peptide: For anti-NR1I2 (ARP36016_P050) antibody is Catalog # AAP36016 (Previous Catalog # AAPP07326)
• Immunogen: The immunogen is a synthetic peptide directed towards the N terminal region of human NR1I2
• Uniprot ID: O75469
• Protein Name: Nuclear receptor subfamily 1 group I member 2
• Publications:

  Dou, W. et al. Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway. J. Pharmacol. Exp. Ther. 345, 473-82 (2013). 23536316

  Sivertsson, L., Edebert, I., Palmertz, M. P., Ingelman-Sundberg, M. & Neve, E. P. A. Induced CYP3A4 expression in confluent Huh7 hepatoma cells as a result of decreased cell proliferation and subsequent pregnane X receptor activation. Mol. Pharmacol. 83, 659-70 (2013). 23264496

• Protein Accession #: NP_003880
• Purification: Affinity Purified
• Nucleotide Accession #: NM_003889
• Tested Species Reactivity: Human
• Gene Symbol: NR1I2
• Predicted Species Reactivity: Human
• Application: IHC, WB
• Predicted Homology Based on Immunogen Sequence: Human: 100%
• Image 1: Human Small Intestine
  
  Immunohistochemistry with Human Small Intestine tissue at an antibody concentration of 5.0ug/ml using anti-NR1I2 antibody (ARP36016_P050)
• Image 2: Human Fetal Lung
  
  Host: Rabbit
  Target Name: NR1I2
  Sample Tissue: Human Fetal Lung
  Antibody Dilution: 1.0ug/ml
• Image 3:
  
  25 ug of the indicated Human whole cell extracts was loaded onto a 12% SDS-PAGE gel. 3 ug/mL of the antibody was used in this experiment.